Identifying and Targeting Angiogenesis-related microRNAs in Ovarian Cancer


Authors: X. Chen, L.S. Mangala, L. Mooberry, E. Bayraktar, S.K. Dasari, S. Ma, C. Ivan, K.A. Court, C. Rodriguez-Aguayo, R. Bayraktar, S. Raut, N. Sabnis, X. Kong, X. yang, G. Lopez-Berestein, A.G. Lacko, and A. K. Sood

Journal: Oncogene

DOI: 10.1038/s41388-019-0862-y

Publication - Abstract

July 09, 2019

Liposomes Other Payloads Oncology

Abstract

Current anti-angiogenic therapy for cancer is based mainly on inhibition of the vascular endothelial growth factor pathway. However, due to the transient and only modest benefit from such therapy, additional approaches are needed. Deregulation of microRNAs (miRNAs) has been demonstrated to be involved in tumor angiogenesis and offers opportunities for a new therapeutic approach. However, effective miRNA-delivery systems are needed for such approaches to be successful. In this study, miRNA profiling of patient data sets, along with in vitro and in vivo experiments, revealed that miR-204-5p could promote angiogenesis in ovarian tumors through THBS1. By binding with scavenger receptor class B type 1 (SCARB1), reconstituted high-density lipoprotein–nanoparticles (rHDL–NPs) were effective in delivering miR-204-5p inhibitor (miR-204-5p-inh) to tumor sites to suppress tumor growth. These results offer a new understanding of miR-204-5p in regulating tumor angiogenesis.


limit search to this category
Advanced Search

Advanced Search

close
  • Publications
  • Application Notes
  • Posters
  • Workshops
  • Videos & Webinars
  • Articles
Search

Browse by Category

  • Application
    • Diagnostic and Imaging
    • Genetic Medicine
    • Hematology
    • Metabolic Disorders
    • Neuroscience
    • Oncology
    • Skeletal Disorders
    • Targeted Drug Delivery
    • Vaccines
    • Other Applications
    • Cell therapy
  • Formulation
    • Liposomes
    • Nucleic Acid Lipid Nanoparticles
    • Polymeric Nanoparticles
    • Other Formulations
  • Payload
    • DNA
    • microRNA
    • mRNA
    • siRNA
    • Small Molecule Drugs
    • Other Payloads


related content

Publication - Summary

May 18, 2019
Annals of Hematology

Lipid Nanoparticle-mediated siRNA Delivery for Safe Targeting of Human CML In Vivo

N. Jyotsana, A. Sharma, A. Chaturvedi, M. Heuser et al.

Nucleic Acid Lipid Nanoparticles siRNA Oncology
A research group led by Micheal Heuser of Hannover University have published a paper in the Annals of Hematology showing effective knockdown of a fusion oncogene in a chronic myeloid leukemia (CML) model by way of siRNA lipid nanoparticle (LNP) in vitro and in vivo Read More


Publication - Abstract

Dec 06, 2018
Advanced Drug Delivery Reviews

Engineering Lymphocytes with RNAi

S. Ramishetti and D. Peer

Oncology Nucleic Acid Lipid Nanoparticles siRNA
Lymphocytes are the gatekeepers of the body's immune system and are involved in pathogenesis if their surveillance is stalled by inhibitory molecules or when they act as mediators for viral entry. Engineering lymphocytes in order to restore their functions is an unmet need in imm...
Read More


Sign Up and Stay Informed
Sign up today to automatically receive new Precision NanoSystems application notes, conference posters, relevant science publications, and webinar invites.
Sign Up